Patents
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
02/2004
02/26/2004WO2002038775A3 METHODS FOR PRODUCING AND PURIFYING RECOMBINANT α-L-IDURONIDASE
02/26/2004WO2001074299A3 Compositions and methods for inhibition of cancer invasion and angiogenesis
02/26/2004US20040039366 Injectable pharmaceutical suspension in a two-chamber vial
02/26/2004US20040039356 Compositions for external preparations
02/26/2004US20040039204 Compositions of n-(methylethaylaminocarbonyl)-4-(-3-methylphenylamino)-3-pyridylsulfonamide and cyclic oligosacccharides
02/26/2004US20040039195 Cucurbituril derivatives, their preparation method and uses
02/26/2004US20040039176 Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
02/26/2004US20040039172 Relates to immunogen for inducing antibodies that neutralize a wide spectrum of HIV primary isolates and method of inducing anti-HIV antibodies using such immunogen
02/26/2004US20040039160 Comprises therapeutic agent, oligopeptide having an isoleucine residue, stabilizing group, and, optionally, a linker group; prodrug is cleavable by an enzyme associated with target cell; antitumor agents
02/26/2004US20040039057 Putrescine, spermine, spermidine or cadaverine with urea or lidocaine
02/26/2004US20040039036 Oral solution containing famotidine and edetic acid or a salt
02/26/2004US20040039022 Storage stable mixtures of (1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol, water, buffers and chelate compounds used as neuroprotectants
02/26/2004US20040039021 Pharmaceutical anti-inflammatory aerosol formulation
02/26/2004US20040039020 Novel pharmaceutical formulation suitable for nebulisation
02/26/2004US20040039011 Administering anticholinergic or bronchodilator agents such as tiotropium bromide for prophylaxis of respiratory system disorders
02/26/2004US20040038963 5,5-Difluoro-3(S)-(pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-(1, 8)-naphthyridin-2-yl)-nonanoic acid; inhibition of bone resorption, restenosis, angiogenesis, retinopathy, macular degeneration, arthritis, metastatic tumor growth, etc.
02/26/2004US20040038953 Medical combination comprising salmeterol and budesonide
02/26/2004US20040038952 Combination of a bile acid and a bioflavonoid; also for treating eye disorders and premenstrual symptoms.
02/26/2004US20040038948 Promoting healing through enhanced regeneration of hard or soft tissue contact with an anti-inflammatory agent; useful in treating periodontal diseases and in orthopedic applications.
02/26/2004US20040038935 Delivery of a therapeutic agent in a formulation for reduced toxicity
02/26/2004US20040038920 Which stimulate lymphoctyes specific for myelin basic protein (MBP) autoantigen, which induces severe experimental autoimmune encephalomyelitis in animal models; cytokines
02/26/2004US20040038916 Delivery of a therapeutic agent in a formulation for reduced toxicity
02/26/2004US20040038903 Gonadotropin releasing hormone antagonists in gel-forming concentration
02/26/2004US20040038899 Polymer stabilized neuropeptides
02/26/2004US20040038892 Chemically-modified human growth hormone conjugates
02/26/2004US20040038885 Carriers for administration of active principles such as drugs or nutriments, cosmetic products or plant health products such as herbicides, pesticides, insecticides, fungicides, etc.
02/26/2004US20040038878 Injectable protein formulations
02/26/2004US20040038876 For use in therapy and diagnosis
02/26/2004US20040038871 Attaching a linker to an amino group of the drug, the linker including an aldehyde or ketone carbonyl group, and forming an oxime by reaction of the carbonyl group with an O-alkylhydroxylamine derivative of the peptide
02/26/2004US20040038870 Methods of drug delivery using sulphated chitinous polymers
02/26/2004US20040038867 Orally administering an amount of an insulin polypeptide-oligomer conjugate to the subject for reducing hypoglycemic episodes
02/26/2004US20040038866 For therapy of insulin deficiency
02/26/2004US20040038864 Use of dimethyl sulfone as isotonicity agent
02/26/2004US20040038859 Containing stabilizing agent comprising matrix metalloproteinase inhibitor
02/26/2004US20040038424 Formaldehyde-ammonium salt complexes for the stabilization of blood cells
02/26/2004US20040038410 Composition for the preservation of viruses
02/26/2004US20040038406 Nanoparticle delivery systems and methods of use thereof
02/26/2004US20040038339 Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
02/26/2004US20040038324 Epothilone resistant cell lines
02/26/2004US20040038303 Comprises use of small particle with appropriate hydrophilic-lipophilic-balance value to deliver anticarcinogenic agents to cells and/or tissues; drug screening
02/26/2004US20040038204 Replacing worn wear strip associated with viral and nonviral gene delivery systems; gene therapy
02/26/2004US20040037907 Parenteral pimaricin as treatment of systemic infections
02/26/2004US20040037897 Treatment of drug resistant organisms
02/26/2004US20040037893 Aqueous composition also including a buffer to keep the pH in the range of 4.0-8.0, a salt of calcium and/or magnesium in a concentration of >15 mM; stabilised against chemical and/ or physical degradation during storage or transportation
02/26/2004US20040037888 Administering intrarectally or to anorectal region aqueous gel composition containing drug effective in such treatment and carrier comprising water soluble cellulose derivative gelling agent, propylene glycol, water
02/26/2004US20040037885 Amphiphilic diblock copolymer, poorly water-soluble drug, biodegradable polymer, liquid poly(ethylene glycol); composition forms implant containing drug and drug containing polymeric micelles, which are slowly released
02/26/2004US20040037883 Controlled release dosage forms
02/26/2004US20040037880 Extended release formulation of divalproex sodium
02/26/2004US20040037879 Oral controlled release forms useful for reducing or preventing nicotine cravings
02/26/2004US20040037877 Flavored gelatin capsule and method of manufacture
02/26/2004US20040037875 Composition for treatment of inflammatory disorders
02/26/2004US20040037874 Delivery of nucleic acid-like compounds
02/26/2004US20040037873 Norethindrone sustained release formulations and methods associated therewith
02/26/2004US20040037872 Active substance-containing adhesive patch comprising diclofenac or a topically acceptable salt thereof; patch composed of outer impermeable backing layer, matrix layer comprising active substance, removable protective layer
02/26/2004US20040037853 Botulinum neurotoxin formulated with a recombinant serum albumin
02/26/2004US20040037836 Comprises nitroglycerin; for preventing adverse effects associated with medical device implantation; for inhibiting platelet deposition; angiotensin converting enzyme inhibitors
02/26/2004US20040037835 Comprises nitroreductase and nicotinamide cofactor; antitumor agents
02/26/2004US20040037834 Rhamm peptide conjugates
02/26/2004US20040037819 Non-polymeric hematopoeitic cell clots for delivery of active agents
02/26/2004US20040037809 Intranasal delivery of interferon- beta yielding improved pharmacokinetic and pharmacodynamic results. In certain aspects of the invention, the interferon- beta is delivered to the intranasal mucosa along with one or more intranasal
02/26/2004US20040037803 A G-CSF solution formulation which is substantially free from proteins as a stabilizer but which contains at least one amino acid or a salt thereof as a stabilizer.
02/26/2004US20040037802 Activated polymeric bicine derivatives such as polypeptides modified with these polymers exhibit reduced immunogenicity/antigenicity and circulate in the blood
02/26/2004US20040037801 Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
02/26/2004US20040037797 Water-in-oil emulsions containing one or more ammonium acryloylodimethyltaurate/vinylpyrrolidone copolymers
02/26/2004US20040037784 Particulate (2S)-3-(4-(((4-(aminocarbonyl)-1-piperidinyl) carbonyl)oxy)phenyl)-2-(((2S)-4-methyl-2-((2-(2-methylphenoxy) acetyl)amino)pentanoyl)amino) propanoic acid or a salt or solvate thereof and one or more suitable excipients for
02/26/2004US20040037783 Pharmaceutical formulation of fluticasone propionate
02/26/2004US20040037778 Iodinated and/or brominated derivatives of aromatic dihydroxy monomers are prepared and polymerized to form radio-opaque polymers. The monomers may also be copolymerized with other dihydroxy monomers. The iodinated and brominated aromatic
02/26/2004US20040037775 Treating and preventing autoimmune diseases. The compositions and methods utilize peptides that are cell-specific. The peptides are conjugated to drugs. The peptide-drug conjugate can be internalized by the targeted cells thereby allowing for
02/26/2004DE20318634U1 Topical compositions for preventing or treating rhinitis, comprising sympathomimetic agent with vasoconstrictive and/or mucosal swelling reducing action and glycosaminoglycan to reduce side-effects
02/26/2004DE20220604U1 Zusammensetzung, enthaltend feine Partikel zur Langzeitfreisetzung für schnell in der Mundhöhle zerfallende Tabletten Composition containing fine particles for sustained release of rapidly disintegrating in the oral cavity tablets
02/26/2004DE20215415U1 Wasserlösliche Medikamentenvorstufen von Propofol Water-soluble prodrugs of propofol
02/26/2004DE10309368A1 Pharmazeutische Zubereitung mit RNA als Cofaktor der Hämostase Pharmaceutical preparation containing RNA as a cofactor of hemostasis
02/26/2004DE10238162A1 Carrier solution for foods, essential ingredients or dietetically- or pharmacologically-active materials contains a thickener
02/26/2004DE10238161A1 Mucosal or topical administration of minerals, e.g. for treating muscle spasms, psoriasis or osteoporosis or promoting wound healing, comprises direct application of mineral solution from ampoule
02/26/2004DE10238144A1 Use of aryl-substituted 3,6-dialkylidene-2,5-piperazinedione derivatives as photostable UV filters in cosmetic or pharmaceutical compositions for protecting human skin or hair against solar radiation
02/26/2004CA2854798A1 Anti-tnf-alpha antibodies in solution and uses thereof
02/26/2004CA2495389A1 Compositions and methods for the diagnosis and treatment of tumor
02/26/2004CA2495345A1 Topical anhydrous and ethanol-free ascomycin compositions
02/26/2004CA2494147A1 Pharmaceutical compositions for buccal delivery of pain relief medications
02/26/2004CA2494132A1 Pharmaceutical composition, metered dose dispenser containing same, and use of pharmaceutical composition and metered dose dispenser in administering pharmaceutical agent to oral membranes
02/26/2004CA2494002A1 Antigenic compositions
02/26/2004CA2493928A1 Nucleic acids and corresponding proteins entitled 273p4b7 useful in treatment and detection of cancer
02/26/2004CA2493925A1 Nucleic acids and corresponding proteins entitled 202p5a5 useful in treatment and detection of cancer
02/26/2004CA2493923A1 Nucleic acids and corresponding proteins entitled 191p4d12(b) useful in treatment and detection of cancer
02/26/2004CA2493921A1 Nucleic acids and corresponding proteins entitled 282p1g3 useful in treatment and detection of cancer
02/26/2004CA2493748A1 Methods and compositions for treatment of macular and retinal disease
02/26/2004CA2493727A1 Improved thermoplastic hydrophilic adhesive compositions for attachment on dry and wet surfaces and with increased water adhesion stability
02/25/2004EP1391513A1 IL-7 drug substance, IL-7 comprising composition, preparation and uses thereof
02/25/2004EP1391426A1 Method for the preparation of a silicic acid comprising extrudate, said extrudate, its use and a pharmaceutical composition comprising the said extrudate
02/25/2004EP1391213A1 Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
02/25/2004EP1391212A1 Oral preparations and supports for oral preparations
02/25/2004EP1391209A1 Protein formulations
02/25/2004EP1391205A1 Pharmaceutical composition with RNA as cofactor of hemostasis
02/25/2004EP1391202A1 Liquid drug preparations
02/25/2004EP1391201A1 Medicinal compositions
02/25/2004EP1390740A1 Methods and formulations for increasing the affinity of a 1? adenosine receptor ligands for the a 1? adenosine receptor
02/25/2004EP1390518A2 Buffer solution for electroporation and a method comprising the use of the same
02/25/2004EP1390495A2 Immunostimulatory oligodeoxynucleic molecules
02/25/2004EP1390494A2 Method for stabilising of nucleic acids
02/25/2004EP1390472A2 Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv